EMA Won’t Budge on PK Studies for Insulin Biosimilars

International Pharmaceutical Regulatory Monitor
A A
The European Medicines Agency has rejected calls from industry to use biosimilar reference products from outside the EU unless they are justified using pharmacokinetic tests.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00